Vir Biotechnology (NASDAQ:VIR) will collaborate with
the National Institutes of Health (NIH) to advance the characterization
and development of human monoclonal antibodies against coronaviruses,
including SARS-CoV-2, the cause of the current outbreak.
Under the terms of the agreement, the company and
NIH’s National Institute of Allergy and Infectious Diseases (NIAID) will
work together to identify and optimize combinations of antibodies
against coronaviruses, including SARS-CoV-2, SARS and MERS. Animal
studies will be conducted to assess immune responses.
Vir has identified a “number” of monoclonals that bind to SARS-CoV-2 that were isolated from people who survived SARS infection.
https://seekingalpha.com/news/3550506-vir-biotech-up-14-premarket-on-nih-coronavirus-collaboration
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.